Protagonist Therapeutics to Participate in Two Upcoming Heal...| MENAFN.COM

Wednesday, 19 January 2022 11:42 GMT

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

(MENAFN- PR Newswire) NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX ) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler.

Presentation Details:

Event: Jefferies London Healthcare ConferenceDate: November 18, 2021Time: 3 a.m. ESTEvent: Piper Sandler 33rd Annual Healthcare ConferenceDate: November 22, 2021Time: 10 a.m. EST

A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at .

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.

Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.

The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds in development include PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates. The Phase 1 study of PN-235 is completed, and Janssen is expected to initiate a Phase 2 study in psoriasis in early 2022. The Phase 1 study with PN-232 is in progress, with study completion expected by mid-2022. Additional research in IBD is expected to initiate in 2022. 

Protagonist is headquartered in Newark, California. For further information, please visit  .

SOURCE Protagonist Therapeutics, Inc.

Related Links


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.